Equillium Announces Pricing of Initial Public Offering
October 12, 2018 08:25 ET
|
Equillium, Inc.
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune...
Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease
September 07, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing...
Kalytera Reports Second Quarter 2017 Financial Results
August 31, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease
August 14, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
Kalytera Announces Changes to its Board of Directors
May 26, 2017 07:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, May 26, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for...
Kalytera Identifies Sites for Planned GvHD Clinical Trials; Company’s Research Gains Support at EBMT 2017
April 25, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived...
Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease
February 22, 2017 09:18 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the...
Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease
February 16, 2017 16:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and...
Kalytera Therapeutics Completes Acquisition of Talent Biotechs
February 16, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantationFour Phase 2 clinical studies evaluating CBD in the...
Mesoblast Announces Pricing Of Public Offering On Nasdaq
November 13, 2015 08:38 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced...